JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?…
Pharma
JNJ·Healthcare·Dividend Aristocrats
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s…
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1…
MDT·Healthcare·Dividend Aristocrats
Medtronic Upgrade Sends Shares Up 5.1% After Q2 Beat
Is the Medtronic Upgrade the start of a bigger rerating, or just a brief earnings-fueled spike? Maik Kemper Editor in…
LLY·Healthcare·Pharma
Eli Lilly LillyDirect +5.4% as Weight Watchers Expands Access
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy? Maik Kemper Editor…
NVO·Healthcare·Pharma
Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum? Maik Kemper…
LLY·Healthcare·Pharma
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik…
LLY·Healthcare·Pharma
Eli Lilly Acquisition $3.8B Push Opens Vaccine Growth Lane
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines? Maik Kemper Editor in…
ABBV·Healthcare·Dividend Aristocrats
AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises? Maik Kemper…
LLY·Healthcare·Pharma
Eli Lilly Earnings +56%: Can the GLP‑1 Boom Last?
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit…